Cargando…
Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis
Purpose: Recently, the U.S. Food and Drug Administration (FDA) approved stiripentol, cannabidiol, and fenfluramine to treat patients with Dravet syndrome (DS). Moreover, soticlestat was determined as a promising new drug for the treatment of DS as it has good efficacy and safety. However, the effica...
Autores principales: | Wu, Jianhua, Zhang, Liu, Zhou, Xi, Wang, Jiajun, Zheng, Xiangyi, Hu, Hankun, Wu, Dongfang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471196/ https://www.ncbi.nlm.nih.gov/pubmed/36120377 http://dx.doi.org/10.3389/fphar.2022.980937 |
Ejemplares similares
-
Comparative antiseizure medications of adjunctive treatment for children with drug-resistant focal-onset seizures: A systematic review and network meta-analysis
por: Zhang, Lanlan, et al.
Publicado: (2022) -
Acute effect of antiseizure drugs on background oscillations in Scn1a
(A1783V) Dravet syndrome mouse model
por: Quinn, Shir, et al.
Publicado: (2023) -
Combined Antiseizure Efficacy of Cannabidiol and Clonazepam in a Conditional Mouse Model of Dravet Syndrome
por: Chuang, Shu-Hui, et al.
Publicado: (2021) -
Effectiveness of antiseizure medications therapy in preventing seizures in brain injury patients: A network meta-analysis
por: Huo, Xianhao, et al.
Publicado: (2022) -
A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway
por: Heger, Katrine, et al.
Publicado: (2020)